The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?

Small molecule orphan drugs: Balancing financial incentives and complex challenges

Whitepaper

For companies pursuing an orphan drug, successfully traversing the path to regulatory submission requires striking the right balance of speed-to-clinic and cost. While there is no one-size-fits-all approach, shared characteristics of successful development projects include:

  • Early and frequent engagement with regulatory authorities
  • Alignment of CMC and clinical activities
  • Transparent communication among internal and external stakeholders
  • An integrated vendor strategy

In this whitepaper, our experts help guide you through the complex challenges of getting your small molecule orphan drug to market faster.